Clinical Cases DDIs

Real-life experiences on the clinical management of Drug-Drug Interactions (DDIs) in the provision of HIV healthcare.

[Clinical Cases DDIs @ClinicalDDIs]

Handling ARV drug interactions? It's crucial to consider not only prescribed medications but also recreational drugs and supplements to ensure comprehensive HIV patient care. Share your cases: https://t.co/TY8t12r0yq
#HIVCare #DrugSafety #ARVInteractions

[Clinical Cases DDIs @ClinicalDDIs]

Stay updated with the latest clinical cases on Drug-Drug Interactions (DDIs) between ARVs and comedications using Clinical Cases DDIs tool! Don't miss out on valuable insights to optimize HIV treatment regimens. Check it out now: https://t.co/Yy0mrCaFZk
#HIVCare #DDIs

[Clinical Cases DDIs @ClinicalDDIs]

Smoking Cessation with Cytisine in #HIV: 58-year-old male on stable BIC/F/TAF starts cytisine for smoking cessation. Dose tapered over 25 days, no adverse events, and HIV load remains <20 copies/mL. Cytisine shows no significant interactions with ART.
https://t.co/QpNjZ08fs9

[Clinical Cases DDIs @ClinicalDDIs]

Managing behavioral symptoms in a 27-year-old with perinatal HIV on ART. Needed risperidone dose increase likely due to interaction with efavirenz. Highlights the importance of monitoring drug interactions in complex cases.
https://t.co/PfobmLObRg
#HIV #Pharmacology #MentalHealth

[Clinical Cases DDIs @ClinicalDDIs]

63yo HIV+ man with stage IV prostate cancer. Rx: degarelix, radiation, then enzalutamide alongside dolutegravir-based ART. Stable pharmacokinetics observed despite drug interactions. Published in AIDS 2022; 36:1603-7. https://t.co/0hy6wmPrbg

[Clinical Cases DDIs @ClinicalDDIs]

📢Share a case study to boost your opportunity of securing a grant for attending your preferred congress in 2025. Don't forget, the greater the number of cases you submit, the better your odds of winning the prize! https://t.co/O43UJZaQQC

[Clinical Cases DDIs @ClinicalDDIs]

Addressing #HeartFailure: Eplerenone initiated Oct '20. Nov '21: Mild hyperkalemia observed, paused Eplerenone, started calcium polystyrene sulfonate. Normal potassium by Nov end. Jan '22: Spironolactone initiated, maintaining balance. Read the case: https://t.co/e0lLp4X5g3

[Clinical Cases DDIs @ClinicalDDIs]

🙌The Clinical Cases DDIs contest is now back on. Share your real-life medical cases, whether they involve positive or negative outcomes in drug interactions. Your experiences matter: https://t.co/iG13dLC4g4

[Clinical Cases DDIs @ClinicalDDIs]

Brivaracetam, a moderate CYP3A4 inducer in vitro, may reduce bictegravir exposure. Though significant interactions aren't expected, real-world cases are valuable. Studies show brivaracetam likely causes no relevant changes in ARV concentration. Learn more: https://t.co/wBWddgHWxK

[Clinical Cases DDIs @ClinicalDDIs]

This case involving a natural product (red yeast rice) and a boosted ARV (elvitegravir/cobicistat) underscores the need for caution with boosted antiretrovirals due to potential interactions that can lead to significant morbidity and mortality. Read more: https://t.co/vhoCDsWLt1

[Clinical Cases DDIs @ClinicalDDIs]

Submit a case on real-life experiences with the clinical management of #DDIs in #HIV healthcare to boost your chances of securing a grant for attending your preferred congress in 2025. 
Report here: https://t.co/zMX6FUw6eD

[Clinical Cases DDIs @ClinicalDDIs]

Dr. José Moltó and Dr. @juanambro1 join Dr. David Burger at Global DDIs Solutions to explore the benefits of documenting real-world outcomes in HIV patients affected by drug-drug interactions.
🎧Tune in now > https://t.co/GQwZRYCVgA

[Clinical Cases DDIs @ClinicalDDIs]

#ClinicalCasesDDIs thrive thanks to our dedicated sponsors like @GileadSciences @MSDEspana and many others. Discover more about their support and contribution: https://t.co/ewz7Tsvml2

[Juan Ambrosioni @juanambro1]

Don’t miss the ‘podcast of the month’ about DDIs: Real-World report of DDIs cases based on our paper:

https://t.co/47VhpIUMSh

https://t.co/k0monpA7nT

[Clinical Cases DDIs @ClinicalDDIs]

Check out this video to see how easily you can use the #ClinicalCasesDDIs website to find real-experience drug interactions with ART in just a few simple steps!
https://t.co/WeAzi4EQPR

[Clinical Cases DDIs @ClinicalDDIs]

Managing #HIV and comorbidities requires careful consideration of DDIs. This case highlights the importance of proactive medication adjustments to mitigate potential risks. Collaboration among healthcare providers is crucial for patient safety.
Read more: https://t.co/EcLuL5kSNv

[Clinical Cases DDIs @ClinicalDDIs]

Call for #abstracts! 📣
Share your research for the upcoming 25th edition of #ANTIVIRALPK and shape the future of clinical pharmacology & antiviral drugs. All accepted abstracts will be published in @BritJClinPharm.
Find the categories & submit > https://t.co/cp07egb0kj

[Clinical Cases DDIs @ClinicalDDIs]

Managing #HIV and #epilepsy simultaneously can be challenging. This case highlights successful adjustments in ART and epilepsy treatment. The patient maintained an undetectable viral load, stable CD4 counts, and no virological failures in the long term.
https://t.co/yRduHt9jNR

[Clinical Cases DDIs @ClinicalDDIs]

Complex cases like this highlight the challenges of managing #HIV with multiple comorbidities. Coadministration with strong inducers can compromise the therapeutic levels of crucial medications, including long-acting parenteral drugs.
Learn more: https://t.co/Yf0HeOsuoS
#DDIs

[Clinical Cases DDIs @ClinicalDDIs]

👏 Special thanks to sponsors like @GileadSciences for powering #ClinicalCasesDDIs. Explore their contributions in advancing medical knowledge: https://t.co/RLJn4XA2jT